Manufacturer switch of anti-seizure drugs may not increase the risk of seizure recurrence in Children: A nationwide study of prescription data in Germany
暂无分享,去创建一个
H. Hamer | S. Gollwitzer | K. Kostev | J. Lang | R. Trollmann | Tamara M. Mueller | Caroline Reindl | J. Stritzelberger | V. Westermayer
[1] A. Ekici,et al. Adherence to Antiepileptic Drugs and the Health Literacy of Caregivers in Childhood Epilepsy. , 2020, Puerto Rico health sciences journal.
[2] H. Hamer,et al. Switching the manufacturer of antiepileptic drugs is associated with higher risk of seizures: A nationwide study of prescription data in Germany , 2018, Annals of neurology.
[3] W. Theodore,et al. Generic antiepileptic drugs—Safe or harmful in patients with epilepsy? , 2018, Epilepsia.
[4] H. Hamer,et al. Adherence to antiepileptic drugs in children and adolescents: A retrospective study in primary care settings in Germany , 2017, Epilepsy & Behavior.
[5] A. Kesselheim,et al. Switching generic antiepileptic drug manufacturer not linked to seizures , 2016, Neurology.
[6] H. Hamer,et al. Nonadherence to antiepileptic drugs in Germany , 2016, Neurology.
[7] R. Alfonso-Cristancho,et al. Definition and Classification of Generic Drugs Across the World , 2015, Applied Health Economics and Health Policy.
[8] H. Hamer,et al. Sociodemographic Disparities in Administration of Antiepileptic Drugs to Adults with Epilepsy in Germany: A Retrospective, Database Study of Drug Prescriptions , 2014, CNS Drugs.
[9] William H Shrank,et al. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. , 2013, JAMA internal medicine.
[10] P. Kwan,et al. Newer drugs for focal epilepsy in adults , 2012, BMJ : British Medical Journal.
[11] B. Caffo,et al. Assessing bioequivalence of generic antiepilepsy drugs , 2011, Annals of neurology.
[12] J. Avorn,et al. Refilling and Switching of Antiepileptic Drugs and Seizure‐Related Events , 2010, Clinical pharmacology and therapeutics.
[13] Patrick Kwan,et al. Definition of refractory epilepsy: defining the indefinable? , 2010, The Lancet Neurology.
[14] Lawrence X. Yu,et al. Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration , 2009, The Annals of pharmacotherapy.
[15] K. Kostev,et al. Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies. , 2009, International journal of clinical pharmacology and therapeutics.
[16] S. Candrilli,et al. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy , 2009, Epilepsy & Behavior.
[17] E. Faught,et al. Nonadherence to antiepileptic drugs and increased mortality , 2008, Neurology.
[18] R. Gross,et al. Generic substitution in the treatment of epilepsy , 2008, Neurology.
[19] J. LeLorier,et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy , 2008, Neurology.
[20] F. Andermann,et al. Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug Classes , 2007, Epilepsia.
[21] M. Prevett,et al. Adherence to treatment in patients with epilepsy: Associations with seizure control and illness beliefs , 2006, Seizure.
[22] Patrick Kwan,et al. Drug development for refractory epilepsy: The past 25 years and beyond , 2017, Seizure.